Eagle Pharmaceuticals Sees FY23 Adj. EBITDA $74M-$80M; Sees Adj. Non-GAAP EPS $4.20-$4.53 Vs $4.42 Est
Preliminary 2023 Guidance
Adjusted EBITDA of $74.0-$80.0 million5
Adjusted non-GAAP earnings per share of $4.20-$4.536
Adjusted non-GAAP R&D expense of $41.0-$45.0 million
